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MicroRNA-377 suppresses initiation and progression of
esophageal cancer by inhibiting CD133 and VEGF
B Li1,2,3,10,11, WW Xu1,2,10,12, L Han1,2, KT Chan4, SW Tsao1,3, NPY Lee3,4, S Law3,4, LY Xu5, EM Li5, KW Chan2,3,6, YR Qin7,
XY Guan3,8, Q Y He9 and ALM Cheung1,2,3
Esophageal cancer is one of the most lethal cancers worldwide with poor survival and limited therapeutic options. The discovery of
microRNAs created a new milestone in cancer research. miR-377 is located in chromosome region 14q32, which is frequently
deleted in esophageal squamous cell carcinoma (ESCC), but the biological functions, clinical signiﬁcance and therapeutic
implication of miR-377 in ESCC are largely unknown. In this study, we found that miR-377 expression was signiﬁcantly
downregulated in tumor tissue and serum of patients with ESCC. Both tumor tissue and serum miR-377 expression levels were
positively correlated with patient survival. Higher serum miR-377 expression was inversely associated with pathologic tumor stage,
distant metastasis, residual tumor status and chemoradiotherapy resistance. The roles of miR-377 in suppressing tumor initiation
and progression, and the underlying molecular mechanisms were investigated. Results of in vitro and in vivo experiments showed
that miR-377 overexpression inhibited the initiation, growth and angiogenesis of ESCC tumors as well as metastatic colonization of
ESCC cells, whereas silencing of miR-377 had opposite effects. Mechanistically, miR-377 regulated CD133 and VEGF by directly
binding to their 3′ untranslated region. Moreover, systemic delivery of formulated miR-377 mimic not only suppressed tumor
growth in nude mice but also blocked tumor angiogenesis and metastasis of ESCC cells to the lungs without overt toxicity to mice.
Collectively, our study established that miR-377 plays a functional and signiﬁcant role in suppressing tumor initiation and
progression, and may represent a promising non-invasive diagnostic and prognostic biomarker and therapeutic strategy for
patients with ESCC.
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INTRODUCTION
Esophageal cancer is the eighth most common cancer worldwide
and this disease is highly lethal, with a 5-year survival rate of
~ 14%.1,2 Although advances in surgical techniques and pre-
operative chemoradiotherapy can improve survival, the majority
of patients are not eligible for surgical resection because many
cases go undetected until the disease is at an advanced stage.
Metastatic spread, recurrence, and resistance to chemo- and
radiotherapy all contribute to the poor prognosis. A lack of robust
predictive biomarkers to guide diagnostic and therapeutic
selection are obstacles in achieving early remission.
MicroRNAs (miRNAs) are short (~22 nucleotides) non-protein-
coding RNAs that can act as post-transcriptional regulators by
binding to complementary sequences in the 3′ untranslated
regions (3′-UTRs) of target mRNAs.3 Increasing evidence supports
that miRNAs are critical regulators of tumorigenesis and cancer
progression, as well as useful diagnostic and prognostic markers in
human cancer.4–7 However, our understanding of how miRNAs
regulate cancer development and progression, particularly how
they may affect tumor initiation and the response of cancer to
chemotherapy is far from adequate. Here, we report that miR-377,
a miRNA conserved among mammals, is signiﬁcantly down-
regulated in esophageal squamous carcinoma (ESCC) cell lines,
and in tumor and serum samples of patients with ESCC. The
coding gene of miR-377 is located in chromosome region 14q32,
which is frequently deleted in ESCC and has one of the largest
miRNA clusters.8,9 However, the biological functions and regula-
tory mechanisms of miR-377 in human cancer are largely
unknown.
In the present study, we examined the expression proﬁles and
prognostic value of miR-377 in ESCC and multiple other cancer
types. In particular, the correlation between miR-377 expression
and ESCC progression, and the role of serum miR-377 as a non-
invasive biomarker in ESCC were evaluated. In addition, the roles
of miR-377 in modulating chemoresistance and in inhibiting
multiple aspects of tumor development including self-renewal,
tumor growth and metastasis, as well as the underlying molecular
mechanisms were investigated. It is widely accepted that tumors
are initiated and maintained by a small population of cancer cells
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termed tumor-initiating cells (TICs) which have the unique abilities
to renew themselves indeﬁnitely and to resist conventional
therapy, and CD133 is one of the most commonly used markers
for identifying TICs.10 However, surprisingly little is known about
the role or signiﬁcance of CD133 in ESCC. Whether CD133
expression has prognostic signiﬁcance in ESCC remains
controversial,11–14 and there is as yet no study showing that
CD133 is a functional TIC marker for ESCC. The aggressive
progression of esophageal cancer is associated with angiogenesis.
Vascular endothelial growth factor (VEGF) plays a predominant
angiogenic role in ESCC.15 Recent meta-analysis studies revealed
that high VEGF expression is associated with worse survival in
ESCC.16,17 This study aims to examine whether the functional role
of miR-377 in ESCC is attributed to its regulation of tumor
initiation and angiogenesis through modulation of CD133 and
VEGF expressions.
MicroRNA-based therapy is increasingly regarded as a novel and
promising strategy in cancer treatment due to advances in miRNA
delivery technologies.18,19 Recent studies reported that tumor
suppressor miRNA mimics could be systemically delivered using
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Figure 1. Expression and prognostic signiﬁcance of miR-377 in ESCC. (a) miR-377 expression in 30 tumor samples relative to the
corresponding normal tissues. (b) Mean miR-377 expression was signiﬁcantly downregulated in primary esophageal cancer (T) compared with
the paired normal tissues (N). (c) Kaplan–Meier analysis of overall survival of 30 ESCC patients stratiﬁed according to tumor miR-377 expression
level. (d) Serum miR-377 level in 114 ESCC patients and 50 healthy control subjects. (e) Correlation between miR-377 expression before
chemoradiotherapy and percentage of residual viable cells in tumor after chemoradiotherapy was analyzed by χ2-test. (f) Kaplan–Meier
analysis of overall survival of 114 patients with ESCC stratiﬁed according to admission serum miR-377 level.
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polyethylenimine-mediated delivery to inhibit cancer progression
in mice.20 Whether re-expressing or replenishing miR-377 might
be a useful therapeutic strategy in treatment of ESCC remains
to be elucidated. We found that systemic administration of
miR-377 oligonucleotide could prevent the growth of tumor
xenograft and experimental metastasis of ESCC cells in mice.
Our study suggests that miR-377 plays a pivotal role in tumor
growth and metastasis, and might be a promising prognostic
biomarker and useful therapeutic agent in the treatment of
patients with ESCC.
RESULTS
Deregulation of miR-377 expression is correlated with poor
chemoresponse and poor survival in esophageal cancer
To study the clinical signiﬁcance of miR-377 in human cancer, we
determined the expression level of miR-377 in 30 pairs of ESCC
tumor and adjacent normal tissues. As shown in Figure 1a, 25
cases (83.3%) had decreased miR-377 expression compared with
corresponding normal tissues. The mean miR-377 expression in
the tumor tissues was about 3-fold lower than that in the paired
normal tissues (Figure 1b). The expression level of miR-377 was
also examined in cell lines, and all 7 ESCC cell lines had
signiﬁcantly lower miR-377 expression compared with an immor-
talized normal esophageal epithelial cell line (Supplementary
Figure S1). Analysis of gene expression proﬁles of several cohorts
of patients from Gene Expression Omnibus (GEO) database
showed that miR-377 was also signiﬁcantly reduced in colon,
ovarian, and breast cancers (Supplementary Figure S2a). Further-
more, although no signiﬁcant correlation was found between
clinicopathological parameters and tumor miR-377 expression
level in the 30 ESCC patients who had upfront surgery
(Supplementary Table S1), patients with low miR-377 expression
in their tumor had signiﬁcantly shorter survival (median
survival = 14.33 months) than the patients with higher tumor
miR-377 expression (median survival = 20.85 months; Figure 1c).
Analysis of the GEO data set of ovarian cancer also indicated that
low miR-377 expression in tumor may predict worse prognosis
(Supplementary Figure S2b). Collectively, our results strongly
suggest that miR-377 may have tumor suppressor function.
Serum miR-377 is a non-invasive biomarker for cancer diagnosis
and prognosis
Recent studies showed that miRNAs in the circulatory system may
serve as promising diagnostic and prognostic biomarkers in
human cancer,19,20 but the expression pattern of miR-377 in the
blood of cancer patients and its feasibility as a non-invasive cancer
biomarker have not yet been reported. To evaluate the potential
of miR-377 as a non-invasive biomarker, we next analyzed the
expression level of miR-377 in serum samples collected from 114
patients on admission with ESCC and 50 healthy individuals. The
mean expression level of miR-377 in the serum of ESCC patients
was about 3-fold lower than that in healthy controls (0.027 ± 0.065
vs 0.098 ± 0.082; Po0.001; Figure 1d). More importantly, we found
that high miR-377 expression level in serum could predict a better
response to chemoradiation with 5-ﬂuorouracil (5-FU) and
cisplatin (DDP), as indicated by the lower percentage of residual
viable cells in the tumor collected during surgery (Figure 1e), and
a signiﬁcant inverse correlation with post-therapy pathologic
T-stage, M-stage, pathological response and resection status (that
is, R classiﬁcation) in the ESCC patients (Table 1). In addition,
higher miR-377 serum expression was positively correlated with
better survival (Figure 1f). Analysis of the GEO data sets showed
that expression of miR-377 was frequently downregulated in the
serum of patients with other types of cancer including
breast cancer, melanoma and lung cancer (Supplementary
Figure S2c). Taken together, these data demonstrated that serum
miR-377 may serve as a non-invasive diagnostic and prognostic
biomarker for ESCC, and as a predictive marker of response to
chemoradiotherapy.
miR-377 modulates chemoresistance and inhibits tumor initiation
and in vivo tumorigenicity of ESCC cells
Given that ESCC patients with lower serum miR-377 level were less
responsive to chemoradiotherapy (Figure 1e), we next examined
the effects of miR-377 on chemoresistance and the results showed
that ectopic miR-377 expression signiﬁcantly enhanced the
sensitivity of ESCC cells to 5-FU and DDP, which are two
commonly used chemotherapeutic drugs for treating esophageal
cancer (Figure 2a). Furthermore, because our data from clinical
sample analysis strongly suggest that miR-377 is a tumor
suppressor in ESCC, we examined its function in tumor initiation.
We found that sphere-forming ESCC cells had lower miR-377
expression compared with the differentiated adherent counter-
parts (Figure 2b), and that ESCC cells with ectopic miR-377
expression had signiﬁcantly reduced sphere formation ability
(Figure 2c), which suggest that miR-377 has a regulatory role in
tumor initiation. We also compared miR-377-overexpressing ESCC
cell lines with respective parental cell lines expressing scrambled
miRNA for ability to form tumors in nude mice. Interestingly,
although a dramatic effect was observed in the group of mice
inoculated with KYSE270-miR-377 cells, as indicated by the almost
Table 1. Correlation between serum miR-377 expression levels and
clinicopathological parameters in ESCC
Variable n Serum miR-377
expressiona
P-value
Low High
Age (years)
⩽ 55 20 9 11
⩾ 55 94 48 46 0.622
Gender
Female 12 6 6
Male 102 51 51 1.000
pT-stage
0/1/2 66 26 40
3/4 26 20 6 0.001
pN-stage
0 53 25 28
1/2/3 39 21 18 0.526
pM-stage
0 84 38 46
1 7 7 0 0.0007
Pathologic stage
pCRb 22 6 16
Othersc/I/II/III/IV 70 40 30 0.014
Pathologic stage
pCRb/Othersc 34 11 23
I/II/III/IV 58 35 23 0.009
R category
R0 80 37 43
R1 12 10 2 0.016
Abbreviations: ESCC, esophageal squamous cell carcinoma; miR, microRNA.
aExpression level of miR-377 was categorized into 'high' and 'low using the
median value as cutoff point. bPathologic complete response. cpT0 with
positive lymph node(s) and/or distant metastasis.
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complete suppression of tumor growth in nude mice, ectopic
miR-377 expression exerted only a modest inhibitory effect on the
tumorigenic potential of KYSE150 cells (Figure 2d). This discre-
pancy suggests that there was a fundamental difference between
the two cell lines in the downstream target(s) of miR-377 that are
associated with tumor formation.
miR-377 directly targets and inhibits CD133 expression
In order to characterize the molecular mechanism by which
miR-377 regulates the functions of ESCC cells, in silico analysis
using TargetScan and Miranda miRNA target prediction algorithms
was performed to identify potential targets of miR-377. Interest-
ingly, CD133, one of the most commonly used marker for TICs, but
not CD90 and CD44, was identiﬁed as a potential target of
miR-377. Since both miR-377 and its complementary binding
sequence in the 3′-UTR of CD133 are highly evolutionally
conserved among different species (Figure 3a), the binding of
miR-377 to the CD133 3′-UTR is likely to have a signiﬁcant
biological function. We found that KYSE150 cells had very low
CD133 expression compared with KYSE270 cells, and that there
was marked decrease of CD133 expression in KYSE270-miR-377
cells (Figure 3b). This difference suggests that miR-377 can
suppress tumor formation by targeting CD133 expression, and
may explain the discrepancy of anti-tumor effect of miR-377
between KYSE150 and KYSE270 (Figure 2d). Western blot data
showed that transfection of miR-377 mimic or miR-377-expressing
plasmid reduced CD133 expression dose dependently in two ESCC
cell lines, as well as in colorectal and liver cancer cell lines
(Figure 3c and Supplementary Figure S3). Moreover, an increase in
CD133 expression in the ESCC cells transfected with anti-miR-377
inhibitor was observed (Figure 3d). Ectopic expression of miR-377
in HEK293 cells resulted in a signiﬁcant dose-dependent decrease
in the relative luciferase activity of CD133 3′-UTR (Figure 3e, left
panel), but there was no inhibition of luciferase activity when the
cells were co-transfected with miR-377 and mutant CD133 3′-UTR
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Figure 2. miR-377 inhibited TIC properties. (a) KYSE270 cells (left panel) and T.Tn cells (right panel) with ectopic miR-377 expression and
corresponding control cells were treated with 5-FU (5 μM), DDP (20 μM) or DMSO for 72 h, and cell viability compared using MTT assay.
(b) Sphere-forming ESCC cells and differentiated adherent counterparts were compared for miR-377 expression by qRT–PCR. (c) Sphere
formation ability of KYSE270 and T.Tn cells transfected with 50 nM miR-377 mimic (left panel), or 0.8 μg miR-377 expressing plasmid (right
panel) was compared with corresponding controls. (d) Growth curves of subcutaneous tumors formed by KYSE150-miR-377 cells (left panel)
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(Figure 3e, right panel), thus conﬁrming that miR-377 can directly
bind to and repress CD133. Furthermore, we made use of 50 pairs
of ESCC tumor and adjacent normal tissues to compare the
expressions of CD133 and miR-377. The signiﬁcantly higher CD133
(Figures 3f and g) and lower miR-377 expression (Figure 3h) in
tumor tissues compared with normal esophageal tissue suggest
that CD133 has an oncogenic role whereas miR-377 has tumor
suppressive function in ESCC. More importantly, the inverse
correlation between miR-377 and CD133 expressions in ESCC
specimens suggests that a regulatory mechanism between
miR-377 and CD133 may have a functional role in tumor
development (Figure 3i).
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CD133+ ESCC cells possess high tumorigenic potential and stem
cell-like characteristics
Although CD133 was reported to be a TIC marker in several cancer
types,10–13 the functional role of CD133 in ESCC has not been
reported. We investigated the correlation between CD133
expression in ESCC cells and TIC properties. Increased CD133
expression was detected in sphere-forming ESCC cells compared
with the differentiated adherent counterparts (Figure 4a). We also
found a positive correlation between CD133 expression and
chemoresistance, which is another important property of TICs,
amongst several ESCC cell lines: the CD133-rich KYSE270 and T.Tn
cells were more resistant to 5-FU and DDP, compared with CD133-
low KYSE150 and HKESC-1 cells (Figure 4b). To validate that CD133
is a marker for esophageal TICs, CD133+ and CD133− cells were
puriﬁed from ESCC cell lines and tumor xenografts for further
investigation. The purity was generally greater than 95%
(Supplementary Figure S4). The sorted CD133+ and CD133−
KYSE410 cells were subcutaneously injected into the left and
right ﬂanks of nude mice, respectively, for comparison of tumor-
initiating ability. Sixty days after cell injection, as few as 5000
CD133+ cells could form tumors in ﬁve out of six (83.3%) mice,
whereas no tumors (none of six mice, 0%) were formed by ten
times as many CD133− cells (Figure 4c and Supplementary
Table S2). Higher capacity for tumorigenicity was also found in
sorted CD133+ KYSE270 cells in NOD/SCID mice, compared with
CD133− cells (Figure 4d and Supplementary Table S3). The ability
of CD133+ cells to undergo self-renewal and display long-term
tumorigenic potential was determined by in vivo serial transplan-
tation. The primary tumor xenografts derived from CD133+
KYSE270 cells were excised from the NOD/SCID mice, re-sorted
into CD133+ and CD133− cells, and re-injected into secondary
mouse recipients. Consistently, only CD133+ but not CD133− ESCC
cells formed tumors with the same histological morphology as the
primary tumors (Figure 4d and Supplementary Table S3), thus
providing direct evidence for self-renewal capacity of CD133+
ESCC cells in vivo. Sphere-formation assay showed that CD133+
ESCC cells had greater ability to form spheres, and successful serial
propagation of dissociated cells from CD133+ cell-derived spheres
further conﬁrmed the self-renewal ability of CD133+ ESCC cells
(Figure 4e). With respect to resistance to conventional chemother-
apeutic drugs, we found that CD133+ ESCC cells were more
resistant to 5-FU and DDP than CD133− cells (Figure 4f). In
addition, treatment with the chemotherapeutic drugs did not
reduce the size or number of spheres formed by CD133+ ESCC
cells (Figure 4g). We also examined whether CD133+ cells
preferentially express the stem cell-associated genes crucial for
maintenance of stem cell properties, and found higher expression
levels of sox2 and LIN28 in CD133+ ESCC cells (Figure 4h). Taken
together, these results demonstrated that CD133 is a valid marker
of ESCC TICs, and that its expression is regulated by miR-377.
CD133 silencing suppresses TIC properties in ESCC cells
To investigate whether CD133 is functionally crucial for main-
tenance of TIC properties, CD133-knockdown experiment was
performed with lentiviral-based short hairpin RNA (shRNA) against
CD133 (shCD133) in KYSE270 cells, which had high CD133
expression, to examine the effects on tumorigenic potential and
stem cell properties. We found that CD133-knockdown reduced the
expression levels of sox2 and LIN28, compared with the scrambled
shRNA control (shCON) (Supplementary Figure S5a). In vivo assay
showed that at a cell dose of 2× 104, only two out of six (33.3%)
mice injected with KYSE270-shCD133 cells developed tumor
whereas KYSE270-shCON cells produced tumors in all of the six
nude mice (100%) examined (Supplementary Figure S5b and
Supplementary Table S4). In addition, inoculation of resuspended
cancer cells from excised primary xenografts into secondary mouse
recipients produced similar results (Supplementary Table S4). When
a larger number of cells (1× 105) were injected, both KYSE270-
shCD133 and KYSE270-shCON cell lines formed tumors in all the
mice in the respective groups (n=6), but the KYSE270-shCD133
tumors were signiﬁcantly smaller (Supplementary Figure S5c)
and with decreased expression levels of Sox2 and LIN28
(Supplementary Figure S5d). The suppressive effect of CD133
repression on self-renewal ability was further conﬁrmed by the
lower serial propagation capacity of KYSE270-shCD133 cells under
sphere-forming culture conditions (Supplementary Figure S5e).
We also found that CD133-knockdown signiﬁcantly enhanced
the sensitivity of esophageal tumor xenografts to 5-FU and
DDP in vivo (Supplementary Figure S5f). Therefore, the above
ﬁndings indicated that CD133 functionally contributes to tumor
initiation and self-renewal capacity, as well as chemoresistance of
ESCC cells.
miR-377 inhibits tumor angiogenesis by directly targeting VEGF
Since KYSE150 cells did not express CD133, the relatively modest
suppressive effect of miR-377 on growth of KYSE150-derived
tumor xenografts (Figure 2d) was likely to be due to mechanisms
other than tumor initiation. Interestingly, histologic comparison of
the tumor xenografts demonstrated signiﬁcantly lower micro-
vessel density (MVD), as determined by CD31-immunostaining, in
the miR-377-overexpressing tumor xenografts, compared with
tumors that expressed control vector, suggesting that miR-377
may affect tumor angiogenesis (Figure 5a). Moreover, conditioned
medium (CM) from ESCC cells expressing miR-377 remarkably
reduced the tube formation and migration ability of human
umbilical vein endothelial cells (HUVECs) while knockdown of
miR-377 in ESCC resulted in increased tube formation and
migration of HUVECs (Figures 5b and c). In the mouse model,
we also observed a reduction of VEGF in the tumor xenografts
established by ESCC cells expressing miR-377, compared with
Figure 3. Direct targeting of CD133 by miR-377 and the inverse correlation of their expression levels in ESCC. (a) Alignment of miR-377 (seed
sequence in bold font) and its corresponding complementary binding sequence in CD133 3′-UTR by TargetScan bioinformatics algorithm
indicated high evolutionary conservation across different species including human (hsa, Homo sapiens), chimpanzee (ptr, Pan troglodytes),
rhesus macaque (mml, Macaca mulatta), and mouse (mmu, Mus musculus). The deletion and mutation sites in CD133 3′-UTR of other species,
compared with human, were underlined. (b) Comparison of CD133 expression in miR-377-overexpressing KYSE150 and KYSE270 cells with the
respective vector control cells by western blot. (c) Western blot analysis of the KYSE270 and T.Tn cells transfected with indicated doses of
miR-377 mimic (left panel) and miR-377-expressing plasmid (right panel), respectively. (d) Effect of anti-miR-377 on CD133 expression in
KYSE270 and T.Tn cells. (e) Left panel, HEK293 cells were transfected with pMir-Fireﬂy-CD133 3′-UTR and pRL-TK, along with different
concentrations of miR-377 mimic or miR-377-expressing plasmid, and the relative luciferase activity of CD133 3′-UTR was determined by dual-
color luciferase assay. Right panel, miR-377 overexpression had no effect on luciferase activity of mutant CD133 3′-UTR. (f and g) CD133 and
actin expressions were determined in 50 pairs of ESCC (T) and matched normal (N) tissues by western blot (six representative pairs are shown
in f). The blots were quantiﬁed using ImageJ and normalized against actin. The expression level of CD133 in primary tumors relative to that of
corresponding normal tissue samples are presented in G (n= 47 after excluding 3 pairs which had undetectable/lack of CD133 expression in
both tumor and normal tissues). (h) miR-377 expression in 50 pairs of esophageal tumor relative to that in matched normal tissues.
(i) Signiﬁcant inverse correlation between miR-377 and CD133 expression levels in 47 pairs of human esophageal tumor and matched normal
tissues (r=− 0.31, Po0.01). Bars, SD; **Po0.01; ***Po0.001 compared with controls.
Clinical and functional signiﬁcance of miR-377 in ESCC
B Li et al
3991
Oncogene (2017) 3986 – 4000
vector control (Figure 5d). In silico analysis showed possible
direct binding between miR-377 and 3′-UTR of VEGF (Figure 5e).
Gain- and loss-of-function experiments using ESCC cell lines
transiently transfected with miR-377 mimic/plasmid or inhibitor
conﬁrmed the inverse regulation of VEGF by miR-377
(Supplementary Figures S6a–b). ESCC cell lines that stably
overexpressed miR-377 showed downregulation of VEGF in both
cell lysates and CM, as determined using western blot and
Enzyme-Linked Immunosorbent Assay (ELISA), respectively
(Figure 5f). In the luciferase reporter assay, overexpression of
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Figure 4. CD133+ ESCC cells possessed increased abilities to self-renew, initiate tumors, and resist chemotherapeutic drugs. (a) Sphere-forming
ESCC cells and adherent counterparts were compared for expressions of CD133 by western blot. (b) KYSE150, HKESC-1, KYSE270 and T.Tn cells
with different endogenous CD133 expression levels as determined by western blot (upper panel) were treated with 5-FU (5 μM), DDP (20 μM),
or DMSO for 72 h, and cell viability determined by MTT assay (lower panel). (c) Representative example of nude mice 60 days after
subcutaneous inoculation of sorted CD133+ (left ﬂank) and CD133− (right ﬂank) KYSE410 cells. See also Supplementary Table S2. (d) About
5000 CD133+ and CD133− cells were sorted from KYSE270-derived tumor xenografts and compared for in vivo tumorigenicity in NOD/SCID
mice (left panel). The procedure was repeated for CD133+ and CD133− cells resorted from tumors derived from CD133+ KYSE270 cells (right
panel). Hematoxylin and eosin (h and e) stained sections of primary and secondary CD133+ KYSE270-derived tumors showed similar
morphology. (e) Comparison of sorted CD133+ and CD133− KYSE270 cells for ability to initiate and form spheres over serial passages. (f) Sorted
CD133+ and CD133− KYSE270 cells were treated with 5-FU (10 μM) or DDP (40 μM) for 72 h, and their drug sensitivity compared using MTT
assay. (g) CD133+ KYSE270 tumor spheres were resistant to 5-FU (10 μM) and DDP (40 μM) treatments. (h) Western blot analysis of CD133, sox2
and LIN28 in sorted CD133+ and CD133- KYSE270 cells. Actin was used as internal control. Bars, s.d.; **Po0.01; ***Po0.001.
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miR-377 led to a dose-dependent decrease in VEGF 3′-UTR
reporter expression (Figure 5g, left panel), but did not exert
repressive effect on luciferase activity of mutant VEGF 3′-UTR
(Figure 5g, right panel), indicating that miR-377 can directly bind
to the 3′-UTR of VEGF. Analysis of 50 primary ESCC tumors and
matched normal esophageal tissue samples showed upregulation
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of VEGF in the majority of tumor samples, and an inverse
correlation between miR-377 and VEGF expressions (Figure 5h).
CD133 and VEGF mediate the effects of miR-377 on cancer
stemness and angiogenesis
To examine the importance of CD133 and VEGF in the functional
roles of miR-377 in cancer stemness and angiogenesis, the expression
levels of CD133 and VEGF in the miR-377-knockdown cells were
inhibited with the corresponding siRNAs (Figure 6a). Sphere-
formation and tube-formation assays were then performed to
determine cancer stemness and in vitro angiogenesis properties.
Consistent with the ﬁndings in Figure 2c, increased sphere-forming
ability was observed in the miR-377-knockdown cells, and this effect
was markedly abrogated upon CD133 inhibition (Figure 6b). More-
over, our results showed that knockdown of VEGF signiﬁcantly
attenuated the promoting effect of miR-377 inhibition on tube-
formation ability in KYSE270 and T.Tn cells (Figure 6c). Collectively,
our data indicated that CD133 and VEGF are crucial for the regulatory
functions of miR-377 in cancer stemness and angiogenesis.
miR-377 inhibits invasion and metastastic colonization
of ESCC cells
We investigated the effect of miR-377 on invasion of ESCC cells
using invasion chamber assay. The results showed that over-
expression of miR-377 dramatically decreased, whereas down-
regulation of miR-377 increased, the invasion potential of KYSE270
and T.Tn cells (Figures 7a and b). Next, KYSE150-luc cells stably
expressing miR-377 were introduced intravenously into the tail
vein of mice for experimental metastasis assay. Lung metastasis
was evaluated and analyzed using bioluminescence imaging. As
showed in Figures 7c and d, overexpression of miR-377 strongly
and signiﬁcantly suppressed lung metastasis. Taken together,
these data suggest that miR-377 plays a role in inhibiting tumor
invasion and metastasis.
Systemically delivered miR-377 mimic suppresses tumor growth
and metastasis
Given that VEGF-mediated angiogenesis and TICs are crucial in
tumor development and maintenance, we explored the thera-
peutic efﬁcacy of miR-377 using mouse models. miR-377
oligonucleotide was injected intravenously into nude mice
bearing established subcutaneous tumor xenografts and the
effect on tumor growth was monitored. The results showed that
systemic delivery of miR-377 oligonucleotide resulted in a
signiﬁcant decrease in tumor burden as compared with treatment
with miR-CON or vehicle (Figure 8a). The anti-tumor effect of
systemically delivered miR-377 was more pronounced for KYSE270
than KYSE150 xenografts, which was consistent with that of
ectopic miR-377 expression (Figure 2d). In addition, signiﬁcant
reduction in MVD was observed in the tumor xenografts of
miR-377-treated mice (Figure 8b). Systemic miR-377 treatment
reduced VEGF expression level in KYSE150 and KYSE270 tumors,
as well as CD133 level in the CD133+ KYSE270 tumors (Figure 8c).
Regular monitoring of body weight of mice showed that there was
no obvious difference among all the groups (Supplementary
Figure S7a), and histological examination of the vital organs
including lungs, liver and kidneys did not reveal any overt changes
in morphology (Supplementary Figure S7b), suggesting that the
miR-377 treatment and the vehicle used for systemic delivery of
miRNA had no toxic effects. In the experimental metastasis study,
treatment with miR-377 led to signiﬁcant decrease in metastatic
burden in the lungs (Figures 8d and e).
DISCUSSION
In this study, we have uncovered that miR-377 plays an
important role in the initiation and progression of ESCC
(Figure 8f). We have provided the ﬁrst evidence that miR-377
expression is frequently downregulated in tumor and serum of
patients with ESCC, and that lower miR-377 expression in primary
tumor signiﬁcantly correlates with unfavorable clinicopathological
characteristics and shorter survival of patients, which strongly
suggest that miR-377 may be a useful non-invasive diagnostic and
prognostic biomarker. Moreover, low miR-377 concentration
in admission serum may be a predictive marker for poor response
to chemoradiotherapy. Deciphering the role of miR-377 in
suppressing tumorigenesis not only has great mechanistic and
functional signiﬁcance in the study of miRNA function in human
cancer, but may also facilitate development of new treatment
strategies.
According to the cancer stem cell hypothesis, tumor cells are
heterogeneous and only a minority of cells with self-renewal
ability within a tumor (that is, TICs) is responsible for tumor
initiation and maintenance.10,21 However, identiﬁcation of valid
TIC markers and development of new therapies that can
selectively target esophageal TICs lag behind other cancers. The
ability of miRNAs to regulate stem cell fate and differentiation by
attenuating the protein levels of various factors that are required
for stem cell functions opens a new dimension of miRNA in
regulation of TIC functions.22–25 Our study was prompted by the
discrepancy in the anti-tumorigenic response of KYSE270 and
KYSE150 cells to ectopic miR-377 expression, with the former cell
line showing complete abolition of tumorigenicity in nude mice
but only a modest effect was observed in the latter (Figure 2d). We
sought to identify possible gene effector(s) participating in this
function which may account for this functional difference. Because
our ﬁndings also showed that higher miR-377 was associated with
better response of the tumors to chemoradiotherapy (Table 1), we
hypothesized that miR-377 may play an important role in
controlling self-renewal and chemoresistance in TICs. In silico
analysis identiﬁed CD133 (Figure 3a), but not CD90 or CD44 which
were previously reported as potential markers for identifying
TICs,26,27 as a possible target of miR-377, leading us to investigate
whether miR-377 may suppress TIC properties through direct
targeting of CD133. Here, we report for the ﬁrst time that CD133 is
a functional and targetable TIC marker for esophageal cancer
Figure 5. miR-377 inhibited tumor angiogenesis by directly targeting VEGF. (a) Tumor xenografts established from KYSE150-miR-CON and
KYSE150-miR-377 ESCC cells were immunostained for CD31 and compared for microvessel density (MVD). (b) Effect of conditioned medium
(CM) from ESCC cells with miR-377 overexpression or knockdown on the tube-formation activity of HUVECs. (c) Effect of conditioned medium
from ESCC cells with manipulated miR-377 expression on migration of HUVECs. (d) Western blot showing the expression of VEGF in tumor
xenografts established from KYSE150-miR-CON and KYSE150-miR-377 cells. (e) Base pairing between miR-377 and 3′-UTR of mammalian VEGF
(hsa, Homo sapiens; ptr, Pan troglodytes; mml, Macaca mulatta; eca, Equine canibus; bta, Bos taurus; mmu, Mus musculus) by TargetScan
bioinformatics algorithms. (f) VEGF expression level in cell lysates and conditioned media of ESCC cells with stable expression of miR-377,
determined using western blot and ELISA respectively, was compared with that of corresponding vector controls. (g) Left panel, dose-
dependent effects of miR-377 plasmids and miR-377 mimic on luciferase activity in HEK293 cells. Right panel, luciferase activity in HEK293 cells
co-transfected with miR-377 and wild type or mutant VEGF 3′-UTR luciferase reporter plasmids as indicated. (h) Expression levels of VEGF in 50
pairs of primary ESCC and matched normal tissues (left and middle panels); inverse correlation was found between VEGF and miR-377
expression levels (right panel). Bars, s.d.; *Po0.05; **Po0.01; ***Po0.001.
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Figure 6. Knockdown of CD133 and VEGF abolished the promoting effects of anti-miR-377 on cancer stemness and angiogenesis.
(a) The increased expression levels of CD133 and VEGF in miR-377-knockdown ESCC cells were inhibited by the siRNAs against CD133 and
VEGF, respectively. (b) The miR-377-knockdown ESCC cells transfected with si-CON or two different siRNAs against CD133 were compared for
ability to form spheres over serial passages. (c) Effects of conditioned medium (CM) from ESCC cells with the indicated manipulation of
miR-377 and VEGF expressions on the tube-formation activity of HUVECs. Bars, s.d.; *Po0.05; **Po0.01.
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(Figure 4). Moreover, we identiﬁed miR-377 as a direct regulator of
CD133 based on several lines of evidence. First, the miR-377
binding site in the 3′-UTR of CD133 is highly conserved among
mammals. Second, miR-377 was downregulated whereas CD133
was upregulated in the sphere-forming cancer cells. Third,
overexpression and knockdown of miR-377 in cancer cells
decreased and increased CD133 expression, respectively, in
transient and stable expression experiments. Fourth, miR-377
could directly bind to the 3′-UTR of CD133 and repress its
luciferase activity. Lastly and more importantly, the expressions of
miR-377 and CD133 were inversely correlated in ESCC. CD133 had
been shown to promote TIC or malignant phenotypes by
increasing the expression of ABCB5, or activating AKT, IL-8 and
MAPK/ERK pathways.28–31 It was also reported that CD133
silencing can induce cancer cell cycle arrest by inhibiting
expression of cytokinesis-related genes.32 Whether these or other
novel mechanisms are operative in CD133+ ESCC cells remains to
be explored. Likewise, whether CD133 has any advantage
compared with CD44 or CD90 as a TIC marker for ESCC, and
whether a combination of cell surface markers should be used to
identify esophageal TICs merit further investigations.
Sustained angiogenesis is an important hallmark of cancer.33
We found that overexpression of miR-377 could suppress tumor
angiogenesis (Figure 5). This was likely to be attributed to the
inhibitory effect of miR-377 on VEGF, which plays a predominant
role in tumor angiogenesis.34 Our results showed direct binding of
miR-377 to the 3′-UTR of VEGF, and a negative correlation
between miR-377 and VEGF expressions in ESCC tissue samples.
Angiogenesis is required for invasive tumor growth and
metastasis.35 More than 90% of mortality from cancer is due to
metastasis.36,37 We investigated the role of miR-377 in inhibiting
cancer cell invasion and distant metastasis, and found that
overexpression of miR-377 decreased, whereas knockdown of
miR-377 increased, the invasiveness of CD133+ ESCC cells
(Figures 7a and b). Furthermore, our in vivo experiment showed
that ectopic expression of miR-377 inhibited metastatic coloniza-
tion of KYSE150 cells despite their lack of CD133 expression
(Figures 7c and d). This phenomenon might be due to the direct
suppressive effect of miR-377 on VEGF in cancer cells. As
mentioned in our recent review,15 VEGF plays a predominant role
in angiogenesis by binding to VEGF receptors. We previously
reported the signiﬁcance of VEGFR1- and VEGFR2-expressing non-
tumor cells in esophageal tumor angiogenesis and metastasis.38 It
is possible that by targeting VEGF, miR-377 may impact on the
function of VEGF-responsive non-tumor cells and deter the
establishment of pre-metastatic niches at distant sites.
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There is increasing recognition that conventional treatment
alone is insufﬁcient in cancer therapy and there is an urgent need
to develop new therapeutic strategies. Accumulating evidence
supports the importance of miRNAs in human cancer, thus making
miRNA-based cancer therapy a promising strategy. Since most
target tissues or organs cannot be accessed by local
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administration of miRNA, systemic administration is the most
widely accepted use of miRNA in the clinic. However, unmodiﬁed,
naked miRNAs are relatively unstable in blood and serum, and are
rapidly degraded by endo- and exonucleases. Virus-mediated
gene delivery, on the other hand, may run the risks of
mutagenesis due to integration of vector genome into host
chromosomes39,40 and possible toxic immune responses.41,42
Combination of miRNA with other forefront technologies includ-
ing nanoparticles, polyethylenimine, liposomes and lipid, has been
developed for effective siRNA/miRNA delivery without detectable
inﬂammatory response or toxic effects.43 For example, a recent
study suggests that treatment with miR-200 members into the
tumor endothelium resulted in marked reductions in metastasis
and angiogenesis.44 Since miR-377 targets both CD133 and VEGF,
and since systemic delivery of synthetic mimics of miR-377 had
signiﬁcant efﬁcacy in suppressing tumor growth, tumor angiogen-
esis as well as metastatic spread (Figure 8), these ﬁndings
underpin the potential of systemic miR-377 therapy as a
promising strategy in the treatment of ESCC and in prevention
of cancer metastasis.
MATERIALS AND METHODS
Cell lines and drugs
Human ESCC cell lines KYSE30, KYSE70, KYSE150, KYSE270, KYSE410
(DSMZ, Braunschweig, Germany),45 HKESC-146 and T.Tn47 were maintained
in RPMI 1640 (Sigma, St. Louis, MO, USA) supplemented with 10% fetal
bovine serum (FBS, Invitrogen, Gaithersburg, MD, USA) at 37 °C in 5% CO2.
HEK293 cells (ATCC) were maintained in DMEM (Sigma) supplemented
with 10% FBS. The cell lines were authenticated by short tandem repeat
proﬁling, and tested for mycoplasma contamination. 5-Fluorouracil (5-FU)
and cisplatin (DDP), purchased from Calbiochem (Darmstadt, Germany),
were dissolved in dimethyl sulfoxide (DMSO).
ESCC tissue and serum samples
Fresh human ESCC and the corresponding adjacent non-tumorous
esophageal samples were collected with informed consent from 50
patients who were treated with surgical resection alone between 2011 and
2012 at the Queen Mary Hospital (Hong Kong) and at the First Afﬁliated
Hospital, Zhengzhou University (Zhengzhou, China) from 2008 to 2010. In
addition, pairs of primary ESCC and matched normal tissue samples were
obtained from an independent cohort of 30 patients with survival data
who had surgical resection without pre-operative chemoradiotherapy at
Queen Mary Hospital. All tissue specimens were snap-frozen immediately
in liquid nitrogen and stored at -80ºC. Admission serum of 114 ESCC
patients who subsequently received neoadjuvant chemoradiotherapy
(with 5-FU and cisplatin) and serum samples from 50 healthy individuals
were obtained from Queen Mary Hospital and Shantou University Medical
College (Shantou, China) respectively. The percentage of residual viable
cells48 in the primary tumor of the 114 ESCC patients (dichotomized into
high and low with median value as cutoff value) was used as a parameter
to evaluate the validity of serum miR-377 as a predictive marker for
response to chemoradiotherapy. Use of all human samples was approved
by the committees for ethical review of research involving human subjects
at the Queen Mary Hospital, Zhengzhou University and Shantou University.
In vitro MTT, sphere formation, cell migration and invasion,
endothelial tube formation, western blot, quantitative real-time
PCR, immunohistochemical staining, luciferase reporter and
site-directed mutagenesis
MTT, migration and invasion assays as well as immunohistochemical
staining of endothelial cells using CD31 antibody (#sc-1506; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and evaluation of microvessel density
(MVD) were carried out as described previously.49 The investigators were
blinded to sample identity in the assessment of MVD in tumor xenograft
sections. Preparation of cell and tumor lysates, and details of western
blotting were described previously.50 QuikChange Lightning Site-Directed
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) was used to
generate mutant constructs for CD133 3′-UTR and VEGF 3′-UTR. Fireﬂy and
Renilla luciferase activities were measured 48 h after transfection using
Dual-Luciferase Reporter System (Promega) according to the manufac-
turer's instructions. More detailed experimental procedures can be found
in the Supplementary Materials and Methods.
Tumorigenicity in nude mice and NOD/SCID mice and
experimental metastasis model
Female BALB/c nude mice and male NOD/SCID mice aged 6–8 weeks were
maintained under standard conditions and cared for according to the
institutional guidelines for animal care. All the animal experiments were
approved by the Committee on the Use of Live Animals in Teaching and
Research of the University of Hong Kong. All animals were sex- and age-
matched in the animal experiments, and littermates were used. The
investigators were not blinded to the experimental groups. The experi-
ment was performed as previously described.51
In vivo delivery of miR-377
miR-377 oligonucleotide or miR-CON (GenePharma, Shanghai, China) was
formulated with a polymer-based agent (in vivo-jetPEI; Polyplus, Illkirch,
France)52–54 according to manufacturer’s instructions and injected
intravenously into mice.
Statistical analysis
The data were expressed as mean± SD. The expression level of miR-377 in
tumor and serum samples was compared with that in normal tissues and
healthy control serum, respectively, using t-test. Sample size in animal
experiments was chosen on the basis of literature documentation of
similar well-characterized experiments, and no statistical method was used
to predetermine sample size. Correlations between miR-377 and CD133/
VEGF expressions, and between miR-377 expression and clinical-
pathological parameters, were assessed using Pearson’s rank correlation
coefﬁcient (two-tailed). The association between miR-377 expression level
and patient survival was plotted using the Kaplan–Meier method, and
statistical differences were compared using the log-rank test. P-values
o0.05 were deemed signiﬁcant. All in vitro experiments and assays were
repeated at least three times.
Figure 8. Systemic delivery of miR-377 oligonucleotide suppressed tumor growth, angiogenesis and metastasis in nude mice. (a–c) ESCC cells
were subcutaneously injected into mice to establish tumor xenograft. Two weeks later when tumor reached ~ 0.5 cm diameter, the mice were
randomized into three different treatment groups to receive weekly intravenous injections of 40 μg miR-377 oligonucleotide, miR-CON
oligonucleotide and vehicle, respectively. (a) Images of tumors (excised 5 weeks after cell implantation) and tumor curves showing the
inhibitory effect of miR-377 oligonucleotide on growth of KYSE150 (left panel) and KYSE270 (right panel)-derived tumor xenografts (n= 6/
group). (b) Quantiﬁcation of CD31-MVD in the tumors of mice treated with miR-377 oligonucleotide, miR-CON oligonuceotide or vehicle.
(c) Western blot showing the expression of CD133 and VEGF in ESCC xenografts. (d and e) KYSE150-luc cells were injected into nude mice via
the tail vein and randomized into four groups. Three groups (n= 6/group) were treated once every two weeks with intravenous injections of
20 μg miR-377 oligonucleotide, miR-CON oligonucleotide and vehicle, respectively, commencing one week after injection of cancer cells. The
4th group (n= 7) received an additional dose of 20 μg miR-377 one day after injection of cancer cells. (d) Bioluminescence imaging and
quantiﬁcation of lung metastasis. (e) Histological evaluation of lung metastasis (H&E staining). (f) Schematic diagram summarizing how
miR-377 suppresses tumor initiation and progression of esophageal cancer by inhibiting CD133 and VEGF. Bars, s.d.; **Po0.01; ***Po0.001.
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